The global Netupitant-Palonosetron FDC market was valued at 30120.73 Million USD in 2021 and will grow with a CAGR of 8.26% from 2021 to 2027, based on Research newly published report.

The prime objective of this report is to provide the insights on the post COVID-19 impact wwhich will help market players in this field evaluate their business approaches. Also, this report covers market segmentation by major market verdors, types, applications/end users and geography(North America, East Asia, Europe, South Asia, Southeast Asia, Middle East, Africa, Oceania, South America).

The netupitant-palonosetron FDC is an oral therapy that targets two critical pathways associated with acute and delayed CINV by blockage of P/NK1 receptors. Netupitant in the central nervous system inhibits the binding of endogenous tachykinin neuropeptide substance, which prevents chemotherapy-induced nausea and vomiting (CINV).Presently, patient pool segment has witnessed large-scale adoption of netupitant-palonosetron FDC drugs due to rise in number of patient undergoing chemotherapy.

By Market Verdors:

By Types:

By Applications:

Key Indicators Analysed

 

Key Reasons to Purchase

LEAVE A REPLY

Please enter your comment!
Please enter your name here